| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, ... New England journal of medicine 351 (4), 337-345, 2004 | 6487 | 2004 |
| Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The lancet oncology 12 (10), 933-980, 2011 | 794 | 2011 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 637 | 2017 |
| Changing patient perceptions of the side effects of cancer chemotherapy N Carelle, E Piotto, A Bellanger, J Germanaud, A Thuillier, D Khayat Cancer 95 (1), 155-163, 2002 | 602 | 2002 |
| Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ... J Clin Oncol 27 (19), 3117-3125, 2009 | 599 | 2009 |
| Impact of EGFR expression on colorectal cancer patient prognosis and survival JP Spano, C Lagorce, D Atlan, G Milano, J Domont, R Benamouzig, ... Annals of oncology 16 (1), 102-108, 2005 | 558 | 2005 |
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The lancet oncology 14 (8), 741-748, 2013 | 447 | 2013 |
| Management of hypertension in angiogenesis inhibitor-treated patients H Izzedine, S Ederhy, F Goldwasser, JC Soria, G Milano, A Cohen, ... Annals of oncology 20 (5), 807-815, 2009 | 428 | 2009 |
| Results of neoadjuvant chemotherapy and radiation therapy in the breast‐conserving treatment of 250 patients with all stages of infiltrative breast cancer C Jacquillat, M Weil, F Baillet, C Borel, G Auclerc, MA De Maublanc, ... Cancer 66 (1), 119-129, 1990 | 371 | 1990 |
| VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management H Izzedine, C Massard, JP Spano, F Goldwasser, D Khayat, JC Soria European Journal of Cancer 46 (2), 439-448, 2010 | 358 | 2010 |
| Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1‐mm thick) Long‐term results of a large European multicentric … D Khayat, O Rixe, G Martin, C Soubrane, M Banzet, JA Bazex, P Lauret, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 328 | 2003 |
| Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with … C Jacquillat, D Khayat, P Banzet, M Weil, P Fumoleau, MF Avril, M Namer, ... Cancer 66 (9), 1873-1878, 1990 | 293 | 1990 |
| Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non–small-cell … JC Soria, E Smit, D Khayat, B Besse, X Yang, CP Hsu, D Reese, ... Journal of Clinical Oncology 28 (9), 1527-1533, 2010 | 289 | 2010 |
| Cyclooxygenase-2 as a target for anticancer drug development JB Méric, S Rottey, K Olaussen, JC Soria, D Khayat, O Rixe, JP Spano Critical reviews in oncology/hematology 59 (1), 51-64, 2006 | 282 | 2006 |
| Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome JP Spano, F Andre, L Morat, L Sabatier, B Besse, C Combadiere, ... Annals of Oncology 15 (4), 613-617, 2004 | 282 | 2004 |
| Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies H Ludwig, D Khayat, G Giaccone, T Facon Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 250 | 2005 |
| Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives JP Spano, R Fagard, JC Soria, O Rixe, D Khayat, G Milano Annals of oncology 16 (2), 189-194, 2005 | 246 | 2005 |
| Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. U Keilholz, C Conradt, SS Legha, D Khayat, C Scheibenbogen, ... Journal of clinical oncology 16 (9), 2921-2929, 1998 | 244 | 1998 |
| overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis? Mathurin, Rixe, Carbonell, Bernard, Cluzel, Bellin, Khayat, Opolon, ... Alimentary pharmacology & therapeutics 12 (2), 111-126, 1998 | 233 | 1998 |
| Metastatic melanoma: chemotherapy E Bajetta, M Del Vecchio, C Bernard-Marty, M Vitali, R Buzzoni, O Rixe, ... Seminars in oncology 29 (5), 427-445, 2002 | 209 | 2002 |
